The Application Of Anlotinib In The Treatment Of Soft Tissue Sarcoma

Objective:In this study,we reviewed the follow-up results of patients with soft tissue sarcoma who could not be completely resected after surgery by two treatment methods,and explored the relationship between the combination of traditional chemotherapy and targeting therapy(alotinib combined with traditional chemotherapy)and the prognosis of patients.To provide clinical basis for the comprehensive treatment of soft tissue sarcoma,so as to better improve the quality of life of patients with soft tissue sarcoma,prolong the survival cycle of patients with soft tissue sarcoma,and delay tumor recurrence and metastasis.Methods:A total of 39 patients with high-grade soft tissue sarcoma who could not be completely removed during surgery were enrolled retrospectively from June 2018 to December 2019,and their general conditions and relevant clinical data were collected.Sixteen patients received routine 8-cycle chemotherapy for soft tissue sarcomas after surgery: doxorubicin60mg/(m2*d)+ ifosfamide 2.5g/(m2*d)d1-3+ mesna 2.5/(m2*d)d1-3 ivdrip,which was recorded as the conventional chemotherapy group.The remaining 23 patients with soft tissue sarcoma received anlotinib(12mg/d,d1-2w,q3w)+ doxorubicin 60mg/(m2*d)+ifosfamide 2.5g/(m2*d)d1-3+ mesna 2.5/(m2*d)d1-3 ivdrip,which was recorded as an anlotinib group.All the 39 patients completed postoperative chemotherapy and regular reexamination.Results:1.Three months after the operation,no patients had local recurrence or pulmonary metastasis,and 16 patients had oral ulcer,hemoptysis,hypertension and other adverse reactions with anlotinib,all of which were grade I and II adverse reactions.No adverse reactions above grade III were found.2.Six months after surgery,10 patients experienced local recurrence,including 2patients in the anlotinib group(both patients had lung metastases)and 8 patients in the traditional chemotherapy group(6 patients had lung metastases).Change the chemotherapy regimen or add immunotherapy in time.3.One year after surgery,22 patients had local recurrence,of which 10 were in the anlotinib group and 12 in the traditional chemotherapy group;16 patients had pulmonary metastases,of which 6 were in the anlotinib group and 10 were in the traditional chemotherapy group.example.Change the chemotherapy regimen or add immunotherapy in time.4.One year after operation,the recurrence rate of 39 patients was 56.4%.Among them,the recurrence rate of patients in the anlotinib group was 43.5%,and the recurrence rate of patients in the traditional chemotherapy group was 75%;39 patients had a lung metastasis rate of 41%,of which the lung metastasis rate was 26% in the anlotinib group,and lung inthe traditional chemotherapy group Ministry transfer rate was 62.5%.It can be seen that the efficacy of the anlotinib group is significantly improved compared with the traditional chemotherapy group in the short term.All were grade I and II,and no adverse reactions above grade III were seen.5.Among the 23 patients in the anlotinib group,20 of them had adverse reactions related to anlotinib,such as hypertension and oral ulcer,all of which were grade I and II adverse reactions,and no adverse reactions above grade III were found.After adjusting the dose,the degree of adverse reactions of all the patients improved.6.By comparing the data of tumor recurrence time between the two groups and comparing the two groups,the tumor recurrence time and lung metastasis time of patients in the amlotinib group were significantly prolonged,and the difference was statistically significant(P < 0.05).It was observed that the recurrence rate and lung metastasis rate of patients in the anlotinib group were significantly lower than those in the traditional chemotherapy group at 3 months,6 months,9 months,1 year and tumor recurrence after surgery,indicating that the efficacy of anlotinib combined with chemotherapy was more significant than that of traditional chemotherapy in inhibiting tumor recurrence and metastasis.Conclusion:1.Anlotinib combined with traditional chemotherapy can significantly inhibit local recurrence and distant lung metastasis in patients with soft tissue sarcoma in a short period of time compared with traditional chemotherapy.2.Anlotinib + traditional chemotherapy is used in patients with soft tissue sarcoma that cannot be completely removed,which helps to extend the progression-free survival and improve the quality of life of patients.3.Anlotinib + traditional chemotherapy is effective in patients with soft tissue sarcoma that cannot be radically removed by surgery,and the adverse reactions can be tolerated.